Table 3. TILs as a predictive biomarker in eTNBC.
| Author, year, reference | Number of TNBC | High TILs cutoff | pCR high TILs | pCR low TILs |
|---|---|---|---|---|
| Abdullaeva et al., 2023, (91) | 132 | 40% | 63.3% | 46.1% |
| Agarwal et al., 2023, (62) | 108 | 60% | 52.90% | 21.10% |
| Sharma et al., 2022, (66) | 117 | 30% | 78% | 45% |
| Gluz et al., 2022, (67) | 336 | 60% | 59.30% | 29% |
| Bianchini et al., 2020, (76) | 260 | 40% | 71% | – |
| Schmid et al., 2020, (92) | 60 | 40% | 74–78% | – |
| Denkert et al., 2018, (55) | 906 | 60% | 50% | 31% |
| Loibl et al., 2019, (68) | 174 | 60% | OR 3.09 HT × IT | |
| Herrero-Vicent et al., 2017, (93) | 164 | 40% | 88% | 9% |
| Tomioka et al., 2018, (94) | 32 | 30% | 30% | 21% |
| Hida et al., 2016, (95) | 48 | 50% | 63% | 17% |
| Denkert et al., 2015, (72) | 314 | 60% | 75% | – |
| Denkert et al., 2010, (54) | 1,058 | 60% | 40% | 7% |
eTNBC, early-stage TNBC; TNBC, triple-negative breast cancer; TILs, tumor-infiltrating lymphocytes; pCR, pathological complete response; OR, odds ratio; HT, high TILs; IT, intermediate TILs.